Shopping Cart 0
Cart Subtotal
AED 0

Trovagene Inc (TROV) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 918

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 1835

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 2753

Details

Summary

Trovagene Inc (Trovagene) is a clinical-stage cancer therapeutics company that focuses on improved cancer care using its technology in tumor genomics. Its lead product, PCM-075, is a polo-like kinase 1 (PLK1) inhibitor that helps treat solid tumor cancers and multiple hematologic malignancies. The company's pipeline products include TROV-052 for the treatment of acute myeloid leukemia; and TROV-053 for the treatment of castration-resistant prostate cancer. Trovagene harnesses its proprietary Precision Cancer Monitoring (PCM) technology to analyze circulating tumor DNA (ctDNA) and clinically actionable markers for the detection and quantitation of oncogene mutations, which enable it to discover patients with possibility to respond to targeted cancer therapies. Trovagene is headquartered in San Diego, California, the US.

Trovagene Inc (TROV)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 6

List of Figures 6

Trovagene Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Trovagene Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Trovagene Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Trovagene Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Trovagene Inc, Medical Devices Deals, 2012 to YTD 2018 11

Trovagene Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Trovagene Inc, Pharmaceuticals & Healthcare, Deal Details 13

Licensing Agreements 13

Trovagene Enters into Patent Licensing Agreement with Massachusetts Institute of Technology 13

Trovagene Enters into Licensing Agreement with Nerviano Medical Sciences for PCM-075 14

TrovaGene Enters Into Licensing Agreement With Quest Diagnostics For NPM1 Marker 15

Trovagene Enters Into Licensing Agreement With Duke University And Duke University Health Systems For NPM1 Marker 16

Trovagene Enters Into Licensing Agreement With Genoptix For NPM1 Marker 17

TrovaGene Enters Into Licensing Agreement With Amedeo Avogadro University And Sapienza University 18

Equity Offering 19

Trovagene Raises USD18 Million in Public Offering of Shares 19

Trovagene Inc-Key Competitors 21

Trovagene Inc-Key Employees 22

Trovagene Inc-Locations And Subsidiaries 23

Head Office 23

Recent Developments 24

Financial Announcements 24

Aug 03, 2018: Trovagene announces second quarter 2018 highlights and financial results 24

May 08, 2018: Trovagene Announces First Quarter 2018 Highlights and Financial Results 26

Feb 26, 2018: Trovagene Announces Fourth Quarter and Full-Year 2017 Results 27

Nov 09, 2017: Trovagene Announces Third Quarter 2017 Company Highlights and Financial Results 29

May 10, 2017: Trovagene Announces First Quarter 2017 Company Highlights and Financial Results 31

Corporate Communications 33

Jun 22, 2018: Trovagene Announces Senior Management Change 33

Sep 20, 2017: Trovagene Strengthens Board of Directors with Appointment of Oncology Development Veteran Dr. Athena Countouriotis 34

Jul 10, 2017: Trovagene Regains Compliance with NASDAQ Listing Requirements 35

Apr 13, 2017: Trovagene Announces the Addition of Dr. Sandra Silberman to its Clinical Advisory Board 36

Product News 38

12/21/2017: Trovagene Announces Activation of Second Clinical Trial Site in Phase 1b/2 Acute Myeloid Leukemia (AML) Trial for PCM-075 38

Dec 12, 2017: Trovagene Announces the Launch of NextCollect Urine Collection and DNA Preservation Kit to Research Laboratories and Pharmaceutical Customers 39

11/13/2017: Trovagene Announces Activation of First Clinical Trial Site in Phase 1b/2 Acute Myeloid Leukemia Trial for PCM-075 40

09/05/2018: Trovagene announces predictive clinical biomarker approach to identify Acute Myeloid Leukemia patients most likely to respond to Onvansertib 41

08/16/2018: Trovagene Announces Completion of Second Dosing Cohort of Patients Treated with Onvansertib (PCM-075) in Ongoing Phase 1b/2 AML Trial 43

08/01/2018: Trovagene Receives Positive Opinion for Orphan Drug Designation in the European Union for PCM-075, Investigational Cancer Drug 45

07/27/2017: Trovagene Announces FDA Approval of IND for Phase 1b/2 Trial of PCM-075 in Patients with Acute Myeloid Leukemia 46

07/06/2017: Trovagene Engages Leading CRO in AML to Conduct Phase 1b/2 Trial of PCM-075 47

06/27/2018: Trovagene Announces Preliminary Clinical Data from First Dosing Cohort Demonstrating Durable Treatment Effect of PCM-075 in Combination with Cytarabine or Decitabine in Patients with Relapsed or Refractory AML 48

06/22/2017: Trovagene Announces Agreement with Global Biopharmaceutical Company to Utilize Trovera ctDNA Tests and Services in Cancer Clinical Trials 50

06/15/2018: Trovagene Announces Completion of First Dosing Cohort of Patients Treated with PCM-075 in Combination with Decitabine in Ongoing Phase 1b/2 AML Trial 51

05/17/2018: Trovagene Announces Completion of First Dosing Cohort of Patients in Ongoing Phase 1b/2 Trial of PCM-075 in Acute Myeloid Leukemia 53

04/17/2018: Trovagene Presents Data at AACR Meeting 2018 on Pharmacodynamic and Tumor Biomarkers During Treatment with PCM-075 and Low-Dose Cytarabine 54

04/16/2018: Trovagene Presents Data at AACR Meeting 2018 Showing Synergy of PCM-075 in Combination with FLT3 Inhibitors in Acute Myeloid Leukemia (AML) 55

04/12/2018: Trovagene Announces Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2018 56

03/05/2018: Trovagene Announces First Patient Successfully Completes Cycle 1 of Treatment with PCM-075 in Combination with Low Dose Cytarabine (LDAC) in AML Trial 57

02/06/2018: Trovagene Announces Completion of Cycle-One Dosing in First Patient Enrolled in its Phase 1b/2 Clinical Trial of PCM-075 in Acute Myeloid Leukemia 58

Product Approvals 59

Aug 29, 2018: Trovagene announces European Commission grants orphan drug designation to Onvansertib (PCM-075) for treatment of acute myeloid leukemia in Europe 59

Aug 15, 2018: Trovagene Receives USAN Approval for Onvansertib as Nonproprietary Name for First-in-Class, 3rd Generation PLK1 Inhibitor Drug Candidate, PCM-075 60

Oct 09, 2017: FDA Grants Orphan Drug Designation to Trovagenes PLK1 Inhibitor, PCM-075, for the Treatment of Acute Myeloid Leukemia (AML) 61

Jun 27, 2017: Trovagene Announces Submission of Investigational New Drug Application to Initiate Phase 1b/2 Clinical Trial of PCM-075 for Acute Myeloid Leukemia 62

Clinical Trials 63

Jun 21, 2018: Trovagene starts enrolment in Phase ll trial of PCM-075 and Zytiga 63

Feb 13, 2018: Yale Cancer Center and Kansas University Cancer Center now actively screening and enrolling patients in Phase 1b/2 Study of PCM-075 in Acute Myeloid Leukemia (AML) 64

Feb 09, 2018: Trovagene Presents Data Showing Synergy of PCM-075 in Combination with Zytiga in Castration-Resistant Prostate Cancer Model at 2018 Genitourinary Cancers Symposium 65

Jan 24, 2018: Trovagene Announces Initiation of UNITE Phase 2 Clinical Trial of PCM-075 in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) 67

Dec 14, 2017: Trovagene Submits Protocol to FDA for Phase 2 Clinical Trial of PCM-075 in Combination with Zytiga for Metastatic Castration-Resistant Prostate Cancer 69

Dec 07, 2017: Trovagene Presents Data Showing Sensitivity of Triple Negative Breast Cancer (TNBC) Cell Lines to PCM-075 and Synergy with Zytiga at San Antonio Breast Cancer Symposium (SABCS) 70

Oct 18, 2017: Trovagene's PLK1 Inhibitor (PCM-075) Demonstrates Synergy with Zytiga (abiraterone acetate) in Castration Resistant Prostate Cancer Tumor Cells 71

Aug 21, 2017: Trovagene's PLK1 Inhibitor PCM-075 Demonstrates Synergy with a HDAC Inhibitor in Non-Hodgkin Lymphoma Cell Lines 72

Aug 16, 2017: Trovagene's PLK1 Inhibitor PCM-075, in Preclinical AML Data, Significantly Enhances the Efficacy of a FLT3 inhibitor in Combination Therapy 73

Jul 25, 2017: Greater selectivity for PLK1, potency, oral bioavailability and short half-life underscore PCM-075s potential as safe and effective treatment for solid tumor and hematological malignancies 74

May 25, 2017: Phase 1 Safety Study Supports Planned Development of PCM-075 in AML 75

Other Significant Developments 76

Jul 09, 2018: Trovagene Presents Outlook for Second Half of 2018 76

Appendix 79

Methodology 79

About GlobalData 79

Contact Us 79

Disclaimer 79


List Of Figure

List of Figures

Trovagene Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Trovagene Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Trovagene Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Trovagene Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Trovagene Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Trovagene Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8

Trovagene Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Trovagene Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Trovagene Inc, Medical Devices Deals, 2012 to YTD 2018 11


List Of Table

List of Tables

Trovagene Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Trovagene Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Trovagene Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Trovagene Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Trovagene Inc, Deals By Therapy Area, 2012 to YTD 2018 10

Trovagene Inc, Medical Devices Deals, 2012 to YTD 2018 11

Trovagene Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Trovagene Enters into Patent Licensing Agreement with Massachusetts Institute of Technology 13

Trovagene Enters into Licensing Agreement with Nerviano Medical Sciences for PCM-075 14

TrovaGene Enters Into Licensing Agreement With Quest Diagnostics For NPM1 Marker 15

Trovagene Enters Into Licensing Agreement With Duke University And Duke University Health Systems For NPM1 Marker 16

Trovagene Enters Into Licensing Agreement With Genoptix For NPM1 Marker 17

TrovaGene Enters Into Licensing Agreement With Amedeo Avogadro University And Sapienza University 18

Trovagene Raises USD18 Million in Public Offering of Shares 19

Trovagene Inc, Key Competitors 21

Trovagene Inc, Key Employees 22

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Trovagene Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Trovagene Inc (Trovagene) is a clinical-stage cancer therapeutics company that focuses on improved cancer care using its technology in tumor genomics. Its lead product, PCM-075, is a polo-like kinase 1 (PLK1) inhibitor that helps treat solid tumor cancers and multiple hematologic malignancies. The company's pipeline products include TROV-052 for the treatment of acute myeloid leukemia; and TROV-053 for the treatment of castration-resistant prostate cancer. Trovagene harnesses its proprietary Precision Cancer Monitoring (PCM) technology to analyze circulating tumor DNA (ctDNA) and clinically actionable markers for the detection and quantitation of oncogene mutations, which enable it to discover patients with possibility to respond to targeted cancer therapies. Trovagene is headquartered in San Diego, California, the US.

Trovagene Inc (TROV)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 6

List of Figures 6

Trovagene Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Trovagene Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Trovagene Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Trovagene Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Trovagene Inc, Medical Devices Deals, 2012 to YTD 2018 11

Trovagene Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Trovagene Inc, Pharmaceuticals & Healthcare, Deal Details 13

Licensing Agreements 13

Trovagene Enters into Patent Licensing Agreement with Massachusetts Institute of Technology 13

Trovagene Enters into Licensing Agreement with Nerviano Medical Sciences for PCM-075 14

TrovaGene Enters Into Licensing Agreement With Quest Diagnostics For NPM1 Marker 15

Trovagene Enters Into Licensing Agreement With Duke University And Duke University Health Systems For NPM1 Marker 16

Trovagene Enters Into Licensing Agreement With Genoptix For NPM1 Marker 17

TrovaGene Enters Into Licensing Agreement With Amedeo Avogadro University And Sapienza University 18

Equity Offering 19

Trovagene Raises USD18 Million in Public Offering of Shares 19

Trovagene Inc-Key Competitors 21

Trovagene Inc-Key Employees 22

Trovagene Inc-Locations And Subsidiaries 23

Head Office 23

Recent Developments 24

Financial Announcements 24

Aug 03, 2018: Trovagene announces second quarter 2018 highlights and financial results 24

May 08, 2018: Trovagene Announces First Quarter 2018 Highlights and Financial Results 26

Feb 26, 2018: Trovagene Announces Fourth Quarter and Full-Year 2017 Results 27

Nov 09, 2017: Trovagene Announces Third Quarter 2017 Company Highlights and Financial Results 29

May 10, 2017: Trovagene Announces First Quarter 2017 Company Highlights and Financial Results 31

Corporate Communications 33

Jun 22, 2018: Trovagene Announces Senior Management Change 33

Sep 20, 2017: Trovagene Strengthens Board of Directors with Appointment of Oncology Development Veteran Dr. Athena Countouriotis 34

Jul 10, 2017: Trovagene Regains Compliance with NASDAQ Listing Requirements 35

Apr 13, 2017: Trovagene Announces the Addition of Dr. Sandra Silberman to its Clinical Advisory Board 36

Product News 38

12/21/2017: Trovagene Announces Activation of Second Clinical Trial Site in Phase 1b/2 Acute Myeloid Leukemia (AML) Trial for PCM-075 38

Dec 12, 2017: Trovagene Announces the Launch of NextCollect Urine Collection and DNA Preservation Kit to Research Laboratories and Pharmaceutical Customers 39

11/13/2017: Trovagene Announces Activation of First Clinical Trial Site in Phase 1b/2 Acute Myeloid Leukemia Trial for PCM-075 40

09/05/2018: Trovagene announces predictive clinical biomarker approach to identify Acute Myeloid Leukemia patients most likely to respond to Onvansertib 41

08/16/2018: Trovagene Announces Completion of Second Dosing Cohort of Patients Treated with Onvansertib (PCM-075) in Ongoing Phase 1b/2 AML Trial 43

08/01/2018: Trovagene Receives Positive Opinion for Orphan Drug Designation in the European Union for PCM-075, Investigational Cancer Drug 45

07/27/2017: Trovagene Announces FDA Approval of IND for Phase 1b/2 Trial of PCM-075 in Patients with Acute Myeloid Leukemia 46

07/06/2017: Trovagene Engages Leading CRO in AML to Conduct Phase 1b/2 Trial of PCM-075 47

06/27/2018: Trovagene Announces Preliminary Clinical Data from First Dosing Cohort Demonstrating Durable Treatment Effect of PCM-075 in Combination with Cytarabine or Decitabine in Patients with Relapsed or Refractory AML 48

06/22/2017: Trovagene Announces Agreement with Global Biopharmaceutical Company to Utilize Trovera ctDNA Tests and Services in Cancer Clinical Trials 50

06/15/2018: Trovagene Announces Completion of First Dosing Cohort of Patients Treated with PCM-075 in Combination with Decitabine in Ongoing Phase 1b/2 AML Trial 51

05/17/2018: Trovagene Announces Completion of First Dosing Cohort of Patients in Ongoing Phase 1b/2 Trial of PCM-075 in Acute Myeloid Leukemia 53

04/17/2018: Trovagene Presents Data at AACR Meeting 2018 on Pharmacodynamic and Tumor Biomarkers During Treatment with PCM-075 and Low-Dose Cytarabine 54

04/16/2018: Trovagene Presents Data at AACR Meeting 2018 Showing Synergy of PCM-075 in Combination with FLT3 Inhibitors in Acute Myeloid Leukemia (AML) 55

04/12/2018: Trovagene Announces Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2018 56

03/05/2018: Trovagene Announces First Patient Successfully Completes Cycle 1 of Treatment with PCM-075 in Combination with Low Dose Cytarabine (LDAC) in AML Trial 57

02/06/2018: Trovagene Announces Completion of Cycle-One Dosing in First Patient Enrolled in its Phase 1b/2 Clinical Trial of PCM-075 in Acute Myeloid Leukemia 58

Product Approvals 59

Aug 29, 2018: Trovagene announces European Commission grants orphan drug designation to Onvansertib (PCM-075) for treatment of acute myeloid leukemia in Europe 59

Aug 15, 2018: Trovagene Receives USAN Approval for Onvansertib as Nonproprietary Name for First-in-Class, 3rd Generation PLK1 Inhibitor Drug Candidate, PCM-075 60

Oct 09, 2017: FDA Grants Orphan Drug Designation to Trovagenes PLK1 Inhibitor, PCM-075, for the Treatment of Acute Myeloid Leukemia (AML) 61

Jun 27, 2017: Trovagene Announces Submission of Investigational New Drug Application to Initiate Phase 1b/2 Clinical Trial of PCM-075 for Acute Myeloid Leukemia 62

Clinical Trials 63

Jun 21, 2018: Trovagene starts enrolment in Phase ll trial of PCM-075 and Zytiga 63

Feb 13, 2018: Yale Cancer Center and Kansas University Cancer Center now actively screening and enrolling patients in Phase 1b/2 Study of PCM-075 in Acute Myeloid Leukemia (AML) 64

Feb 09, 2018: Trovagene Presents Data Showing Synergy of PCM-075 in Combination with Zytiga in Castration-Resistant Prostate Cancer Model at 2018 Genitourinary Cancers Symposium 65

Jan 24, 2018: Trovagene Announces Initiation of UNITE Phase 2 Clinical Trial of PCM-075 in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) 67

Dec 14, 2017: Trovagene Submits Protocol to FDA for Phase 2 Clinical Trial of PCM-075 in Combination with Zytiga for Metastatic Castration-Resistant Prostate Cancer 69

Dec 07, 2017: Trovagene Presents Data Showing Sensitivity of Triple Negative Breast Cancer (TNBC) Cell Lines to PCM-075 and Synergy with Zytiga at San Antonio Breast Cancer Symposium (SABCS) 70

Oct 18, 2017: Trovagene's PLK1 Inhibitor (PCM-075) Demonstrates Synergy with Zytiga (abiraterone acetate) in Castration Resistant Prostate Cancer Tumor Cells 71

Aug 21, 2017: Trovagene's PLK1 Inhibitor PCM-075 Demonstrates Synergy with a HDAC Inhibitor in Non-Hodgkin Lymphoma Cell Lines 72

Aug 16, 2017: Trovagene's PLK1 Inhibitor PCM-075, in Preclinical AML Data, Significantly Enhances the Efficacy of a FLT3 inhibitor in Combination Therapy 73

Jul 25, 2017: Greater selectivity for PLK1, potency, oral bioavailability and short half-life underscore PCM-075s potential as safe and effective treatment for solid tumor and hematological malignancies 74

May 25, 2017: Phase 1 Safety Study Supports Planned Development of PCM-075 in AML 75

Other Significant Developments 76

Jul 09, 2018: Trovagene Presents Outlook for Second Half of 2018 76

Appendix 79

Methodology 79

About GlobalData 79

Contact Us 79

Disclaimer 79


List Of Figure

List of Figures

Trovagene Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Trovagene Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Trovagene Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Trovagene Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Trovagene Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Trovagene Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8

Trovagene Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Trovagene Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Trovagene Inc, Medical Devices Deals, 2012 to YTD 2018 11


List Of Table

List of Tables

Trovagene Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Trovagene Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Trovagene Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Trovagene Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Trovagene Inc, Deals By Therapy Area, 2012 to YTD 2018 10

Trovagene Inc, Medical Devices Deals, 2012 to YTD 2018 11

Trovagene Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Trovagene Enters into Patent Licensing Agreement with Massachusetts Institute of Technology 13

Trovagene Enters into Licensing Agreement with Nerviano Medical Sciences for PCM-075 14

TrovaGene Enters Into Licensing Agreement With Quest Diagnostics For NPM1 Marker 15

Trovagene Enters Into Licensing Agreement With Duke University And Duke University Health Systems For NPM1 Marker 16

Trovagene Enters Into Licensing Agreement With Genoptix For NPM1 Marker 17

TrovaGene Enters Into Licensing Agreement With Amedeo Avogadro University And Sapienza University 18

Trovagene Raises USD18 Million in Public Offering of Shares 19

Trovagene Inc, Key Competitors 21

Trovagene Inc, Key Employees 22

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Trovagene Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.